Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Rebecca S. Heist's publication output changed over time?
ScholarIQpublication output · 2009–2022
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2022.
1
2
2
1
2
1
2
1
20092011201520162018202020212022
What are the most-cited papers on Rebecca S. Heist?
ScholarIQmost cited works
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata, Subba R. Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer S. Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman
S24207032. 20113,582 CitationsOPEN ACCESS
Lung cancer
Alesha Thai, Benjamin Solomon, Lecia V. Sequist, Justin F. Gainor, Rebecca S. Heist
The Lancet. 20212,586 Citations
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>
Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson, Subba R. Digumarthy, Daniel B. Costa, Rebecca S. Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott, Jeffrey Settleman, Susumu Kobayashi, Eugene J. Mark, Scott J. Rodig, Lucian R. Chirieac, Eunice L. Kwak, Thomas J. Lynch, A. John Iafrate
Journal of Clinical Oncology. 20091,889 CitationsOPEN ACCESS
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, David P. Carbone, Mary Pinder-Schenck, Suzanne L. Topalian, F. Stephen Hodi, Jeffrey A. Sosman, Mario Sznol, David F. McDermott, Drew M. Pardoll, Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Matthew D. Hellmann, Georgia Kollia, Ashok Gupta, Julie R. Brahmer
Journal of Clinical Oncology. 20151,197 CitationsOPEN ACCESS
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer
Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo‐Jack, Shirish M. Gadgeel, Katherine R. Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth L. Lockerman, Tiffany G. Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba R. Digumarthy, Colleen L. Channick, Colleen Keyes, Gad Getz, Dora Dias‐Santagata, Rebecca S. Heist, Jochen K. Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman, Alice T. Shaw
Cancer Discovery. 20161,157 CitationsOPEN ACCESS
Related on ScholarIQ
Harvard University
Institution
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Paper
Lung cancer
Paper
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>
Paper
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Paper
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer
Paper